Neutre
Pfizer's stock remains stable near analyst target of $28 following Q2 earnings.
Ce briefing n’est pas encore disponible dans cette langue — version anglaise affichée.
Pfizer's stock price has remained stable near the analyst target of $28 following the release of its Q2 2026 earnings report. The company reported an adjusted earnings per share of $0.77, surpassing analyst expectations of $0.68, and confirmed its full-year 2026 earnings guidance of $2.80 to $3.00 per share. Despite these positive results, the stock's performance has been relatively flat, indicating a neutral market sentiment.
Points clés
- Pfizer's stock price remains near the analyst target of $28 following Q2 earnings.
- The company reported an adjusted earnings per share of $0.77, exceeding analyst expectations of $0.68.
- Pfizer confirmed its full-year 2026 earnings guidance of $2.80 to $3.00 per share.
- Despite positive earnings, the stock's performance has been relatively flat, indicating neutral market sentiment.
Sources
- Die Pfizer-Inc.-Aktie legt nach Q2-2026-Zahlen mit solider Prognose zuAD HOC NEWS · August 21, 2026
- Pfizer, Inc. (PFE) Stock Hold: $28.08 → $32.28 (-8.3%) | Aug 2026TrendMatrix · August 23, 2026
- Pfizer Just Raised Its 2026 Guidance -- but the Boost Leans Heavily on a Drug Running Out the Patent ClockThe Motley Fool · August 11, 2026
- Pfizer (PFE) Could Be 10% Undervalued Following Raised Revenue GuidanceSimply Wall St News · August 13, 2026
Généré par IA à partir de sources d'actualités publiques. Ceci n'est pas un conseil financier.
